Our results suggest that flow cytometric detection of CCR1 and CCR2 on the PB leukemic cells, along with CD38, could serve as an additional indicator predicting the high risk of disease progression in CLL patients at diagnosis. This evidence concerns the gene CCR2 and B-cell chronic lymphocytic leukemia.